Pakistan will be manufacturing the anti viral drug Remdsivir within two months according to Special Assistant on National Health Services Dr Zafar Mirza. The drug will also be available for COVID-19 patients in Pakistan. Dr Mirza said that five companies in the world had been granted the license to manufacture the drug, Pakistani company being one of them.
The antiviral drug Remdesivir has shown promising results in the treatment of COVID-19 in clinical trials. Two trials of the drug were carried out: one by the US National Institute of Allergy and Infectious Diseases and the other by Gilead Sciences. More than 1,000 patients across the globe took part in NIAID’s trial. Treatment with Remdesivir was compared with supportive care with a placebo.
Remdesivir, an antiviral medicine, has cured nearly all coronavirus patients after the clinical trial. A hospital in Chicago administering Remdesivir reported that the patients recovered from fever and respiratory difficulties. Remdesivir is a product of Gilead Sciences, an American biotechnology company. Following the outbreak of Coronavirus in Wuhan, several laboratory tests identified Remdesivir as the potential cure of COVID-19 disease.